Status:
COMPLETED
A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Male Participants
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.
Eligibility Criteria
Inclusion
- Participants must have a body mass index of 18.0 to 32.0 kg/m2, inclusive.
- Participants will be required to always use a latex or other synthetic condom with spermicide during any sexual activity
- Participants must refrain from donating sperm during the entire study and for at least 90 days from dose of study drug.
Exclusion
- Participant must not have had any clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months prior to admission to the clinic.
- Participant must not be currently employed in a job requiring radiation exposure monitoring.
- Participant must not have had any major surgery within 4 weeks of study drug administration that could impact upon the absorption of study drug
Key Trial Info
Start Date :
October 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2023
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06088264
Start Date
October 31 2023
End Date
December 22 2023
Last Update
March 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortrea Clinical Research Unit
Madison, Wisconsin, United States, 53704